Drug Trial Radar · NCT03674567
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
323
Actual
Start
Sep 25, 2018
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companiesIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Sep 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is a Phase 1/2, open-label, sequential-group, dose-escalation and cohort expansion study to determine the safety and preliminary anti-tumor activity of FLX475 as monotherapy and in combination with pembrolizumab. The study will be conducted in 2 parts, a dose-escalation phase (Part 1) and a cohort expansion phase (Part 2). In Part 1 of the study, subjects will be enrolled in sequential cohorts treated with successively higher doses of FLX475 as monotherapy or in combination with pembrolizumab. In Part 2 of the study, subjects will be initially enrolled in Stage 1 of parallel expansion cohorts of FLX475 as monotherapy or in combination with pembrolizumab.
Conditions
- Advanced Cancer
Interventions
FLX475 (tivumecirnon)Drug
tablet
pembrolizumab (KEYTRUDA®)Drug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability of FLX475 as a Single Agent and in Combination With Pembrolizumab Measured by the Incidence of Adverse Events, Including Dose-limiting Toxicities and Maximum Tolerated DoseTime frame: Approximately 18 weeks
- Overall Response Rate in Subjects Treated With FLX475 as a Single Agent and in Combination With PembrolizumabTime frame: Through study completion (approximately 2 years)
Locations
35 sites in 6 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
City of Hope
Duarte, California
University of California, Los Angeles JCCC Clinical Research Unit
Los Angeles, California
Yale Cancer Center
New Haven, Connecticut
Georgetown - Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia
Comprehensive Hematology and Oncology, LLC
St. Petersburg, Florida
Moffitt Cancer Center
Tampa, Florida
Emory Winship Cancer Institute
Atlanta, Georgia
University of Chicago
Chicago, Illinois
University of Louisville Hospital/James Graham Brown Cancer Center
Louisville, Kentucky
Johns Hopkins University
Baltimore, Maryland
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Quantum Santa Fe
Santa Fe, New Mexico
New York Presbyterian Hospital-Columbia University Medical Center
New York, New York
Carolina BioOncology Institute
Huntersville, North Carolina
Mary Crowley Cancer Research Center
Dallas, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
University of Washington
Seattle, Washington
Austin Hospital
Heidelberg, Victoria, Australia
Linear Clinical Research Limited
Nedlands, Western Australia, Australia
Queen Mary Hospital - Lymphoma
High West, Hong Kong
Queen Mary Hospital
High West, Hong Kong
Prince of Wales Hospital
Shatin, Hong Kong
Chungbuk National University Hospital
Jungbuk, South Korea
Seoul National University
Seoul, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
National Cheng Kung University Hospital
Tainan, Taiwan
Chi Mei Meidcal Center
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
King Chulaongkorn Memorial Hospital
Bangkok, Thailand
Ramathibodi Hospital
Bangkok, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.